$33.85+0.07 (+0.21%)
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TG Therapeutics, Inc. in the Healthcare sector is trading at $33.85. The stock is currently 17% below its 52-week high of $40.99, remaining 6.2% above its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why TGTX maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMV...
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Event context and recent stock move TG Therapeutics (TGTX) has caught investor attention recently as its share price closed at $35.33, with returns of 3% over the past day and about 17% over the past month. See our latest analysis for TG Therapeutics. The recent 17.5% 1 month share price return and 20.7% year to date share price return stand in contrast to a 7.8% decline in the 1 year total shareholder return. This suggests that momentum has picked up after a weaker patch. If TG Therapeutics...
TG Therapeutics completes enrollment in a phase III study of subcutaneous Briumvi for treating RMS in adults, with data expected by late 2026 or early 2027.
The trial will compare the radiological, safety, and clinical outcomes of subcutaneous versus IV Briumvi.